PT - JOURNAL ARTICLE AU - Christine Klein AU - Max Borsche AU - Alexander Balck AU - Bandik Föh AU - Johann Rahmöller AU - Elke Peters AU - Jan Knickmann AU - Miranda Lane AU - Eva-Juliane Vollstedt AU - Susanne A. Elsner AU - Nadja Käding AU - Susanne Hauswaldt AU - Tanja Lange AU - Jennifer E. Hundt AU - Selina Lehrian AU - Julia Giese AU - Alexander Mischnik AU - Stefan Niemann AU - Florian Maurer AU - Susanne Homolka AU - Laura Paulowski AU - Jan Kramer AU - Christoph Twesten AU - Christian Sina AU - Gabriele Gillessen-Kaesbach AU - Hauke Busch AU - Marc Ehlers AU - Stefan Taube AU - Jan Rupp AU - Alexander Katalinic TI - Cohort-based surveillance of SARS-CoV2 transmission mirrors infection rates at the population level: a one-year longitudinal study AID - 10.1101/2021.05.10.21256966 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.10.21256966 4099 - http://medrxiv.org/content/early/2021/06/06/2021.05.10.21256966.short 4100 - http://medrxiv.org/content/early/2021/06/06/2021.05.10.21256966.full AB - Background More than one year into the COVID-19 pandemic, important data gaps remain on longitudinal prevalence of SARS-CoV-2 infection at the population level and in defined risk groups, efficacy of specific lockdown measures, and on (cost-)effective surveillance.Methods The ELISA (Lübeck Longitudinal Investigation of SARS-CoV-2 Infection) study invited adult inhabitants (n=∼300,000) from the Lübeck area (Northern Germany) and enrolled 3051 participants (∼1%); 1929 population-matched and 1645 with high-exposure based on profession. The one-year study period (03/2020-02/2021) spanned massive influx of tourism in the summer, rise of infection rates in the fall/winter 2020/2021, and two lockdowns. Participants were screened seven times for SARS-CoV-2 infection using PCR and antibody testing and monitored with an app-based questionnaire (n=∼91,000).Results Cohort (56% female; mean age: 45.6 years) retention was 75%-98%; 89 persons (3.5%) were antibody- and/or PCR-positive. Seropositivity was almost 2-fold higher in men and increased risk detected in several high-exposure groups (highest for nurses, followed by police, army, firemen, and students). In May 2020, 92% of the infections were missed by PCR testing; by February 2021, only 29% remained undiagnosed. “Contact to COVID-19-affected” was the most relevant risk factor. Other factors, such as frequent use of public transportation, shopping, close contacts at work, and extensive tourism in the summer did not impact infection rates.Conclusions We i) provide a model for effective, regional surveillance; ii) identify infection risk factors informing public health measures; iii) demonstrate that easing of lockdown measures appears safe at times of low prevalence in the presence of continuous monitoring.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was sponsored by the Federal Ministry for Education and Research (BMBF), the State of Schleswig-Holstein, by the Tuberculosis Foundation SH, by the University of Luebeck, and by a crowd-funding campaign organized by the University of Luebeck.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of the University of Luebeck The ELISA (Luebeck Longitudinal Investigation of SARS-CoV-2 Infection) study was approved by the ethics committee of the University of Luebeck (Az. 20-150)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available from the corresponding authors upon request.